Bayer Settles Baycol AG Stuits $8 million
Repeat legal violations: The record of recidivism by major drug manufacturers is a matter of public record.
Reputations for Sale ? BMJ-BBC-Panorama-Seroxat/ Paxil
BBC-Panorama–third in a series: The Secrets of Seroxat. "In the interests of patients and professional integrity" is to show those who have sold their reputations "intolerance and exposure."
Showdown Looms in Congress Over Drug Advertising on TV
The FDA is salivating in expectation of increased funding from the drug industry–ostensibly to speed up the reviewing process for TV ads.
Role of Litigation in Defining Drug Risks_JAMA / BMJ
Documents uncovered during the course of litigation shed light on real risks of drug-induced harm that would not otherwise be known.
NEJM- Caught Covering Up for National Kidney Foundation–an indudstry front group
Readers of the New England Journal of Medicine should be forewarned: The information in the pages of the NEJM is tainted by industry influence, its professional and scientific integrity are tainted.
Blood substitute`a disaster’ in trial Northfield still plans toseek FDA approval
American medicine is fast descending into lethal medicine thanks to FDA officials who lend the government seal of approval to drugs and experiments that kill.
Eli Lilly Documents Show Risks of Zyprexa were deliberately played down_NYT
NY Times reports: In March 2002, Lilly rejected plans to give psychiatrists guidance about how
to treat diabetes, "worrying that doing so would tarnish Zyprexa's reputation."
NIH Secrets Government Funded Data Concealment_Lenzer-New Republic
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
Dangerous Deception: Hiding the Evidence of Adverse Drug Effects_NEJM
FDA's slip-shod approval of defective, harmful drugs, accompanied by rubber stampped endorsements by compromised FDA advisory committees may be reaching a boiling point.
Whistleblower: Confessions of Healthcare Hitman
The Whistleblower: Confessions of a Healthcare Hitman by Dr. Peter Rost, published by Soft Skull Press.
Potent Narcotic ‘Lollipop’ Becomes Best Seller_WSJ
Off-label prescribing of drugs for unapproved uses puts consumers at high risk of harm–but it is the single most lucrative marketing strategy.
VIOXX WITHDRAWAL: FDA TO JOIN AUDIO CONFERENCE ON NOVEMBER 10
VIOXX WITHDRAWAL: FDA TO JOIN AUDIO CONFERENCE ON NOVEMBER 10 Mon, 8 Nov 2004 To hear from FDA Office of New Drugs Acting Director Sandra Kweder, MD, in an interactive discussion of what the withdrawal of the blockbuster drug means for the agencys drug safety programs, the COX-2 inhibitor class…